Matches in Wikidata for { <http://www.wikidata.org/entity/Q96162174> ?p ?o ?g. }
Showing items 1 to 44 of
44
with 100 items per page.
- Q96162174 description "artículu científicu espublizáu en xunu de 2020" @default.
- Q96162174 description "im Juni 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q96162174 description "scientific article published on 06 June 2020" @default.
- Q96162174 description "wetenschappelijk artikel" @default.
- Q96162174 description "наукова стаття, опублікована 6 червня 2020" @default.
- Q96162174 name "Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan's health care system" @default.
- Q96162174 name "Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan's health care system" @default.
- Q96162174 type Item @default.
- Q96162174 label "Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan's health care system" @default.
- Q96162174 label "Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan's health care system" @default.
- Q96162174 prefLabel "Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan's health care system" @default.
- Q96162174 prefLabel "Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan's health care system" @default.
- Q96162174 P1433 Q96162174-0FF53CCF-4EAD-4654-93C2-21F25705ECF8 @default.
- Q96162174 P1476 Q96162174-B2DDA432-2ECD-444C-B35C-4BF033556882 @default.
- Q96162174 P2093 Q96162174-254DFABE-503B-42E3-B2D2-DAD38F6F6E58 @default.
- Q96162174 P2093 Q96162174-26E8FD7F-237A-449D-84CB-F24A83D33ACB @default.
- Q96162174 P2093 Q96162174-46B843DA-4704-4D68-A119-2DC3AF021515 @default.
- Q96162174 P2093 Q96162174-89608450-63CB-491B-8B1F-6CFC54111C61 @default.
- Q96162174 P2093 Q96162174-969B9A3E-0E16-4996-91BE-A9742D991CFE @default.
- Q96162174 P2093 Q96162174-DEBFA022-7A4B-4DD1-BA58-F376883DB6F4 @default.
- Q96162174 P2093 Q96162174-F5836F20-D7AD-4BB4-A263-A55823A1BD44 @default.
- Q96162174 P31 Q96162174-8645EBFC-B8B2-4DAD-9E7F-C061DA617054 @default.
- Q96162174 P356 Q96162174-F3A388AB-D366-41AA-B5E8-5E02D7955CCD @default.
- Q96162174 P50 Q96162174-B14A4DC1-4122-44CD-BC88-8C0855382812 @default.
- Q96162174 P577 Q96162174-63B7EE1A-BC48-4956-85E7-3270970C1691 @default.
- Q96162174 P698 Q96162174-E4B0D22A-7BDD-4B5B-A9C8-7889EF8AD75A @default.
- Q96162174 P921 Q96162174-F196A272-DE9A-4546-9EFD-1493C41A1B64 @default.
- Q96162174 P356 S10198-020-01207-7 @default.
- Q96162174 P698 32506280 @default.
- Q96162174 P1433 Q24883230 @default.
- Q96162174 P1476 "Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan's health care system" @default.
- Q96162174 P2093 "Hsuan-Ying Chen" @default.
- Q96162174 P2093 "Huang-Tz Ou" @default.
- Q96162174 P2093 "Sin-Syue Li" @default.
- Q96162174 P2093 "Tsai-Yun Chen" @default.
- Q96162174 P2093 "Wei-Tse Fang" @default.
- Q96162174 P2093 "Yao-Chun Wen" @default.
- Q96162174 P2093 "Yu-Wen Lo" @default.
- Q96162174 P31 Q13442814 @default.
- Q96162174 P356 "10.1007/S10198-020-01207-7" @default.
- Q96162174 P50 Q58208080 @default.
- Q96162174 P577 "2020-06-06T00:00:00Z" @default.
- Q96162174 P698 "32506280" @default.
- Q96162174 P921 Q18553852 @default.